secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K
Filed at:   2026-05-12T21:03:02+00:00
Accession:  0001140361-26-020845
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gyre Therapeutics' NDA for F351 accepted by China's NMPA for CHB-induced liver fibrosis
--------------------------------------------------------------------------------

- NDA for F351 (hydronidone) accepted by CDE of China's NMPA for chronic hepatitis B-induced liver fibrosis.
- NMPA granted priority review status in March 2026; this is Gyre's first NDA for the F351 program.
- If approved, F351 could address tens of millions of HBV patients in China at risk of fibrosis and cirrhosis.
- Dr. Ying Luo noted positive CDE interactions and the potential of F351 as an innovative therapeutic option.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000114036126020845/0001140361-26-020845-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000114036126020845/ef20073066_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-020845

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer